Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$1.67 - $2.94 $291,720 - $513,568
-174,683 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$1.8 - $2.32 $314,429 - $405,264
174,683
174,683 $314,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.54B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Virtus Fund Advisers, LLC Portfolio

Follow Virtus Fund Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus Fund Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus Fund Advisers, LLC with notifications on news.